Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab is an anti-idiotypic antibody that mimmics glycolylated gangliosides (NeuGcGM3) in its idiotype.
See overall survival chart in patients treated with Vaxira®
See progression-free survival graph in patients treated with Vaxira®
Vaxira® is a biopharmaceutical product that stimulates the body to produce an immune response against lung cancer.
Vaxira® is administered intradermally using a fine needle.
You should not receive Vaxira® if you are allergic (hypersensitive) to, or have a history of being allergic to any of the chemical or biological compounds in the Vaxira® formulation.